摘要
目的:探讨非小细胞肺癌(Non-small cell lung cancer,NSCLC)患者血浆和肺癌组织中CD163分子表达水平以及对肺癌细胞侵袭和增殖的影响。方法:选取我院35例NSCLC患者为研究组,35例同期体检的健康人群为对照组,采用Real-time RCR检测肺癌患者肿瘤组织和血浆中CD163表达水平;采用小分子干扰RNA(siRNA)抑制MH-2中CD163分子的表达,再与A549共培养,transwell法观察CD163分子对A549侵袭的影响,CCK-8法检测A549增殖的变化。结果:CD163分子在NSCLC患者血浆中的表达水平显著高于正常健康人群,差异具有统计学意义(P<0.05),在肿瘤组织中的表达显著高于癌旁组织,差异具有统计学意义(P<0.05);转染后,A549的侵袭和增殖能力显著下降,差异具有统计学意义(P<0.05)。结论:CD163在NSCLC患者血浆和肺癌组织中高表达,并可增强肺癌细胞的侵袭和增殖能力。
Objective： To investigate the expression of CD163 in the plasma and tumor tissue of non-small cell lung cancer（ NSCLC） patients,and the effects of cancer cell migration and proliferation. Methods： 35 cases of NSCLC patients in our hospital as the study group,and 35 healthy volunteers as control group,we used Real-time RCR to detect the expression of CD163 in the plasma and tumor tissue of NSCLC patients. Using small interfering RNA（ siRNA） to inhibit the expression of CD163 in MH-2,and co-culture with A549. The level of cancer cell migration was observed by transwell and the level of cell proliferation was observed by CCK-8. Results： The expression of CD163 in the plasma and tumor tissue of NSCLC patients was significantly higher than the control group,the difference was statistically significant（ P〈0. 05）; after the expression of CD163 was suppressed in MH-2,the levels of cancer cell migration and proliferation were significantly decreased,the difference was statistically significant（ P〈0. 05）. Conclusion： The expression of CD163 in the plasma and tumor tissue of NSCLC patients is increased,and may elevate the levels of cancer cell migration and proliferation.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2016年第3期410-413,416,共5页
Chinese Journal of Immunology
